Lizamma Antony

Lysine-specific demethylase 1 (LSD1) is emerging as a critical mediator of tumor progression in metastatic castration-resistant prostate cancer (mCRPC). Neuroendocrine prostate cancer (NEPC) is increasingly recognized as an adaptive mechanism of resistance in mCRPC patients failing androgen receptor axis-targeted therapies. Safe and effective LSD1 inhibitors are necessary to determine antitumor response in prostate cancer models.

Corresponding Author W. Nathaniel Brennen PhD Department of Oncology, Sidney Kimmel Comprehensive Cancer Center (SKCCC), Johns Hopkins University, Baltimore, Maryland, USA Department of Pharmacology and Molecular Science, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA Correspondence John T. Isaacs, PhD and W.

Metrics Downloaded 0 times History Received 17 March 2020 Accepted 14 October 2020 Published online 5 November 2020 Information © 2020 Future Medicine Ltd KeywordsAuthor contributions WN Brennen, DLJ Thorek, W Jiang, TE Krueger, SR Denmeade and JT Isaacs conceived of the idea and wrote the manuscript. WN Brennen, TE Krueger and L Antony performed the experiments. All authors reviewed and approved the manuscript.